Phase I Trial of EGFR/IL13Rα2 CAR T Cells for Recurrent High-Grade Gliomas
A phase I trial is investigating the safety and dosing of EGFR/IL13Rα2 pool-CAR T cells administered locoregionally for recurrent or progressive high-grade gliomas.
Phase I
Oncology / CAR T Cell Therapy
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase I trial of EGFR/IL13Rα2 CAR T cells represents a potential breakthrough in the treatment of recurrent high-grade gliomas, a challenging area in oncology. Positive trial outcomes could significantly enhance competitive positioning and market share for companies involved in CAR T cell therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include trial results on safety and efficacy, as well as any subsequent trials or partnerships that may arise from this research.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.